<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01062100</url>
  </required_header>
  <id_info>
    <org_study_id>OCOG-2009-THORN</org_study_id>
    <nct_id>NCT01062100</nct_id>
  </id_info>
  <brief_title>Study To Investigate the Feasibility and Safety of A Dedicated High Resolution Nuclear Breast Imaging Camera</brief_title>
  <acronym>THORN</acronym>
  <official_title>The Hamilton Prospective Pilot Study To Investigate the Feasibility and Safety of A Dedicated High Resolution Nuclear Breast Imaging Camera</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ontario Clinical Oncology Group (OCOG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ontario Clinical Oncology Group (OCOG)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the feasibility, acceptability and safety of using a molecular breast imaging
      (MBI) Gamma Camera in women at high risk of developing breast cancer
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the feasibility, safety and acceptability to patients of the MBI Gamma camera.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To explore the ability of the MBI Gamma camera to detect breast cancer.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>nuclear breast imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nuclear breast imaging using MBI Gamma camera</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>nuclear breast imaging using MBI Gamma camera</intervention_name>
    <description>nuclear breast imaging using MBI Gamma camera in addition to MRI</description>
    <arm_group_label>nuclear breast imaging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females ≥18 years of age

          -  Undergoing annual breast MRI because of a high risk of breast cancer due to any of the
             following:

               -  Known BRCA1 or BRCA2 mutation carriers, or is untested for BRCA but is a first
                  degree relative of a BRCA mutation carrier

               -  History of radiation to the chest between 10-30 years of age (e.g. Hodgkin's
                  Disease)

               -  History of Cowdens or Li Fraumeni Syndrome

               -  A first degree relative with Cowdens or Li Fraumeni Syndrome

               -  Prior breast biopsy positive for lobular carcinoma in situ (LCIS) or atypical
                  lobular hyperplasia or atypical ductal hyperplasia (ADH)

               -  Family history consistent with a hereditary breast cancer syndrome and estimated
                  personal lifetime cancer risk ≥25% using the IBIS risk evaluator

        Exclusion Criteria:

          -  Pregnant or lactating

          -  History of invasive breast cancer or ductal carcinoma in situ (DCIS)

          -  Unable to undergo MRI because of:

               -  Renal dysfunction with an estimated creatinine clearance of &lt; 30 ml/min
                  calculated using the Cockcroft-Gault formula

               -  Implanted ferrous metal prostheses

               -  Claustrophobia

               -  Medical or psychological conditions that on assessment, make them unable to
                  complete the procedure

               -  Known allergies to Gadolinium-DTPA

          -  Known allergies to Sestamibi (Miraluma or Cardiolite)

          -  Prior bilateral mastectomy

          -  Prior breast biopsy or surgery within 3 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Pond</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ontario Clinical Oncology Group - McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karen Gulenchyn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamilton Health Sciences Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2010</study_first_submitted>
  <study_first_submitted_qc>February 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2010</study_first_posted>
  <last_update_submitted>February 15, 2013</last_update_submitted>
  <last_update_submitted_qc>February 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>molecular breast imaging</keyword>
  <keyword>MRI</keyword>
  <keyword>gamma camera</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

